Skip to main navigation
Menu
  • Focus & Strategy
  • Innovation & Pipeline
  • Disease Areas
  • Investors & Media
  • Contact
Focus & Strategy
  • President’s Letter
  • Leadership
  • Board of Directors
Innovation & Pipeline
  • Roluperidone (MIN-101)
  • Seltorexant (MIN-202)
  • MIN-301
Disease Areas
  • Schizophrenia
  • Insomnia and Mood Disorders
  • Parkinson’s Disease
Investors & Media
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
  • Stock Information
  • Investor FAQs
  • Contact Us
Corporate Governance
  • Executive Management
  • Board of Directors
  • Committee Composition
  • Contact the Board
Financials & Filings
  • SEC Filings
  • Annual Reports and Proxies
  • Quarterly Results
  • Key Ratios
Stock Information
  • Historic Stock Lookup
  • Investment Calculator
  • Analyst Coverage
Minerva Neurosciences logo
  • Focus & Strategy
    • President’s Letter
    • Leadership
    • Board of Directors
  • Innovation & Pipeline
    • Roluperidone (MIN-101)
    • Seltorexant (MIN-202)
    • MIN-301
  • Disease Areas
    • Schizophrenia
    • Insomnia and Mood Disorders
    • Parkinson’s Disease
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Executive Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact Us
  • Contact

INVESTORS & MEDIA

  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
    • SEC Filings
    • Annual Reports and Proxies
    • Quarterly Results
    • Key Ratios
    • Form 8937
  • Stock Information
  • Investor FAQs
  • Contact Us

Shareholder Tools

Printed Materials
Email Alerts
Downloads
RSS
Print
Share

  • RSS

Financials & Filings

Show all

2022

Q4
  • Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates
  • Form 10-K

Proxy Statements

Filing date View
Apr 26, 2022 View HTML
0001193125-22-120328.pdf
0001193125-22-120328.rtf
0001193125-22-120328.xls
Apr 30, 2021 View HTML
0001193125-21-145239.pdf
0001193125-21-145239.rtf
0001193125-21-145239.xls

Form 10-K

Filing date View
Mar 08, 2023 View HTML
0000950170-23-006577.pdf
0000950170-23-006577.rtf
0000950170-23-006577.xls
EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
Mar 01, 2022 View HTML
0001564590-22-007853.pdf
0001564590-22-007853.rtf
0001564590-22-007853.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Form 10-Q

Filing date View
Nov 09, 2022 View HTML
0000950170-22-023496.pdf
0000950170-22-023496.rtf
0000950170-22-023496.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Aug 09, 2022 View HTML
0000950170-22-015754.pdf
0000950170-22-015754.rtf
0000950170-22-015754.xls
EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

Shareholder Tools

Printed Materials
Email Alerts
Downloads
RSS
Print
Share

  • RSS
  • About Us

    • President's Letter
    • Leadership
    • Board of Directors
  • Disease Areas

    • Schizophrenia
    • Insomnia and Mood Disorders
    • Parkinson’s Disease
  • Innovation & Pipeline

    • Roluperidone (MIN-101)
    • Seltorexant (MIN-202)
    • MIN-301
  • (617) 600-7373
    email us
    Privacy Policy | Terms of Use

    Biotech Web Design Company ©2017 Minerva Neurosciences